China disciplines 80 officials linked to major vaccine scandal

Image
AFP Beijing
Last Updated : Feb 02 2019 | 8:30 PM IST

China's corruption watchdog on Saturday said it has disciplined more than 80 officials linked to a major vaccine scandal last summer that inflamed public fears over the safety of domestically produced drugs.

Changchun Changsheng Biotechnology -- a major Chinese manufacturer of rabies vaccines -- was slapped with a USD 1.3 billion fine last October after it was found to have fabricated records.

Four officials from the China Food and Drug Administration (CFDA), including a deputy director, have been handed over to prosecutors, the Central Commission for Discipline Inspection said in a statement Saturday.

The brief statement did not say what they were alleged to have done.

The graft watchdog also said it would "seriously deal with" more than 80 other provincial or local officials from multiple government organisations, without offering details.

These officials have already been fired or demoted, it said. Authorities earlier said the faulty rabies vaccines did not enter the market. But the case provoked outrage from customers fed up with recurring product-safety scandals, particularly in the drug sector.

The drug company's chairwoman and 14 employees were arrested after the scandal came to light last July, while more than a dozen national, provincial and local officials were sacked.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 02 2019 | 8:30 PM IST

Next Story